medicationPrescription only (US)Ezetimibe (Zetia) is FDA-approved as a cholesterol absorption inhibitor, used alone or combined with a statin (e.g., Vytorin) for hyperlipidemia and cardiovascular risk reduction
EzetimibeBenefits, Dosage & Interactions
Also known as: Zetia
Ezetimibe is a prescription cholesterol medicine that blocks the NPC1L1 transporter in the small intestine, cutting absorption of dietary and biliary cholesterol. It is typically taken in the morning. The reported plasma half-life is about 22 hours, which shapes dosing frequency.
How much Ezetimibe do people take?
Ezetimibe 10 mg once daily, either combined with a statin or (in EWTOPIA 75) with dietary counseling alone, across the cited cardiovascular outcome trials. Route reported: Oral tablet. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Ezetimibe — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 3 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials and regulatory approval on file.
Quick answer
Ezetimibe is a prescription cholesterol medicine that blocks the NPC1L1 transporter in the small intestine, cutting absorption of dietary and biliary cholesterol. Used alone it lowers LDL cholesterol by roughly 15–20 percent; added to a statin it delivers a further reduction and, in the IMPROVE-IT trial, fewer cardiovascular events. It is not a statin and does not inhibit cholesterol synthesis.
- Class
- Cholesterol absorption inhibitor (NPC1L1)
- Brand names
- Zetia, Ezetrol; with simvastatin as Vytorin/Inegy
- Label strength
- 10 mg tablet, once daily
- Typical LDL effect
- About 15–20% alone; additive on top of a statin
- Key trial
- IMPROVE-IT — fewer cardiovascular events added to simvastatin
- Common side effects
- Diarrhea, joint pain, fatigue; myopathy uncommon
Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.
Plasma half-life
~22 h
Typical timing
in the morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Ezetimibe in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Ezetimibe entry is written from. Each number matches an inline marker above.
- [1]Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesCannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P · The New England Journal of Medicine · 2015 · Peer-reviewed · PMID 26039521
- [2]Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trialKim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK · Lancet · 2022 · Peer-reviewed · PMID 35863366
- [3]Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled TrialOuchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y · Circulation · 2019 · Peer-reviewed · PMID 31434507
References & Evidence
Sources on this page that document Ezetimibe dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Ezetimibe?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Ezetimibe, sold under the brand name Zetia, is a medication used to treat high cholesterol. It works by reducing the absorption of cholesterol from the small intestine into the body. This mechanism of action is distinct from statins, which work by inhibiting cholesterol production in the liver. Ezetimibe can be used alone, but it is often prescribed in combination with statin medications to achieve greater reductions in low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. It is approved for use in primary hyperlipidemia (high cholesterol), homozygous familial hypercholesterolemia (a severe inherited form of high cholesterol), and homozygous sitosterolemia (a rare genetic disorder leading to high plant sterol levels). The compound's chemical structure allows it to selectively target the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is crucial for cholesterol absorption (FDA label).
What does the research say about Ezetimibe?
Tap a section to expand.
Ezetimibe's primary mechanism of action involves inhibiting the absorption of cholesterol by the small intestine. Specifically, it targets the Niemann-Pick C1-Like 1 (NPC1L1) protein, located on the brush border of enterocytes (cells lining the small intestine). By blocking this protein, ezetimibe prevents dietary and biliary cholesterol from entering the bloodstream. This reduction in cholesterol absorption leads to a decrease in the delivery of cholesterol to the liver. The liver then upregulates its LDL receptors, which in turn removes more LDL cholesterol from the blood, resulting in lower plasma LDL-C levels. This mechanism is complementary to that of statins, which reduce cholesterol synthesis in the liver. When ezetimibe is used with a statin, the combined effect can lead to more significant reductions in LDL cholesterol than either medication alone. Ezetimibe does not significantly affect the absorption of fat-soluble vitamins (A, D, E, K) or triglycerides (FDA label, PubChem).
Source for this section: Sources for How does Ezetimibe work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of ezetimibe is its ability to lower elevated levels of total cholesterol, LDL cholesterol, and apolipoprotein B, while also increasing high-density lipoprotein (HDL) cholesterol in some cases. By reducing LDL cholesterol, ezetimibe contributes to a decreased risk of atherosclerotic cardiovascular disease, which includes conditions like heart attack and stroke. Clinical trials, such as the IMPROVE-IT study, have demonstrated that adding ezetimibe to statin therapy can significantly reduce the incidence of cardiovascular events compared to statin therapy alone in patients with acute coronary syndrome (Cochrane, FDA label). It is particularly beneficial for individuals who cannot tolerate statins, or for whom statins alone do not achieve target cholesterol levels. Ezetimibe is also used in the treatment of homozygous sitosterolemia, where it effectively reduces plasma sitosterol and campesterol levels.
Evidence supporting ezetimibe's efficacy comes from numerous clinical trials. The IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study demonstrated that in patients with acute coronary syndrome, the addition of ezetimibe to simvastatin significantly reduced the primary composite endpoint of cardiovascular death, major coronary event, or nonfatal ischemic stroke, compared to simvastatin monotherapy (Cochrane). This study provided robust evidence for the cardiovascular benefit of ezetimibe beyond just lipid lowering. Other studies have consistently shown that ezetimibe, either alone or in combination with statins, effectively reduces LDL-C levels. For instance, a meta-analysis of multiple trials concluded that ezetimibe monotherapy consistently lowers LDL-C by approximately 18-20% (PubChem). When combined with statins, it provides an additional 15-20% LDL-C reduction on top of statin effects. These findings underpin its role in current guidelines for managing hyperlipidemia (NIH ODS).
Common side effects associated with ezetimibe include upper respiratory tract infection, diarrhea, joint pain (arthralgia), sinus inflammation (sinusitis), and pain in the extremities. When ezetimibe is taken with a statin, side effects can also include muscle pain (myalgia), elevated liver enzymes (transaminases), and headache. More rarely, serious adverse effects such as hypersensitivity reactions (including rash, angioedema, and anaphylaxis), pancreatitis, gallstones (cholelithiasis), and inflammation of the gallbladder (cholecystitis) have been reported. It's important to note that the overall incidence of serious side effects is generally low. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Ezetimibe?: Jumps to this entry in the sources and references list at the end of the page.
Patients using ezetimibe should be monitored for potential adverse reactions. Liver function tests should be performed before and during therapy when ezetimibe is co-administered with a statin, especially if symptoms suggesting liver injury develop. Discontinue ezetimibe if unexplained muscle pain, tenderness, or weakness occurs, particularly if accompanied by malaise or fever, or if markedly elevated creatine phosphokinase (CPK) levels are present, as this could indicate myopathy or rhabdomyolysis. Use with caution in patients with moderate to severe hepatic insufficiency, as ezetimibe exposure is significantly increased in this population. It is not recommended for use in patients with active liver disease (FDA label, MedlinePlus). This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Ezetimibe?: Jumps to this entry in the sources and references list at the end of the page.
Ezetimibe is contraindicated in individuals with known hypersensitivity to any component of the medication. When ezetimibe is combined with a statin, the contraindications for the statin medication also apply to the combination therapy. These typically include active liver disease, including unexplained persistent elevations in serum transaminases. Pregnancy and lactation are generally contraindications for statins, and therefore for the combination of ezetimibe with a statin. Ezetimibe monotherapy is not contraindicated in pregnancy or lactation, but its use should be carefully considered against potential risks and benefits (FDA label). This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Ezetimibe not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Avoid concurrent use of ezetimibe with bile acid sequestrants (such as cholestyramine, colestipol, colesevelam) as they can significantly reduce the oral bioavailability of ezetimibe. If co-administration is necessary, ezetimibe should be taken at least two hours before or four hours after administration of a bile acid sequestrant. Caution is advised when co-administering ezetimibe with cyclosporine, as cyclosporine can increase ezetimibe levels. Close monitoring of cyclosporine concentrations should be performed. Fibrates, particularly gemfibrozil, can increase the risk of cholelithiasis (gallstones) and should generally be avoided with ezetimibe. If co-administration with gemfibrozil is deemed necessary, concomitant use should be avoided if possible due to increased risk of adverse effects. Warfarin and other coumarin anticoagulants may have their anticoagulant effects enhanced when co-administered with ezetimibe; thus, prothrombin time should be closely monitored (FDA label, DrugBank). This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Ezetimibe?: Jumps to this entry in the sources and references list at the end of the page.
Ezetimibe is typically taken once daily, in the morning. It can be taken with or without food, as food does not significantly affect its absorption (FDA label). If taken concurrently with a statin, it can be taken at the same time as the statin. If a bile acid sequestrant is also prescribed, ezetimibe should be taken at least two hours before or four hours after the bile acid sequestrant to prevent impaired absorption of ezetimibe.
Source for this section: Sources for When should you take Ezetimibe?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Ezetimibe is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Ezetimibe?
Frequently asked questions about Ezetimibe
Ezetimibe reduces cholesterol by blocking a specific protein (NPC1L1) in the small intestine that is responsible for absorbing cholesterol directly from food and bile. By preventing this absorption, less cholesterol enters the bloodstream, leading to lower LDL ('bad') cholesterol levels (PubChem).
Yes, Ezetimibe is often prescribed in combination with statin medications. This combination provides a more significant reduction in LDL cholesterol than either medication alone, as they work through different mechanisms to lower cholesterol (FDA label).
The typical dosage for Ezetimibe must be set by a licensed clinician, as it depends on the individual's specific condition, response to treatment, and whether it's being used alone or in combination with other medications. Do not self-medicate or alter prescribed doses.
While Ezetimibe works to reduce cholesterol absorption, it is still important to follow a cholesterol-lowering diet recommended by your healthcare provider. Ezetimibe is not a substitute for healthy lifestyle choices (MedlinePlus).
Ezetimibe has an elimination half-life of approximately 22 hours. This means it takes about 22 hours for half of the medication to be cleared from your system. Due to this relatively long half-life, it is typically taken once daily (DrugBank).
Ezetimibe is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Ezetimibe is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 22 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Ezetimibe with no sign-up.
Ezetimibe is typically taken in the morning. The reported plasma half-life is about 22 hours, which is what drives how often it is redosed. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a medication like Ezetimibe with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Ezetimibe: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 22 hours, once-daily dosing is the usual pattern for Ezetimibe. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 22 hours, a single missed dose of Ezetimibe usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Ezetimibe the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Statins block HMG-CoA reductase and reduce how much cholesterol the liver makes; ezetimibe blocks how much is absorbed from the gut. Because the mechanisms differ, the effects add up, which is why the two are often prescribed together when a statin alone does not reach the LDL target or the statin dose is limited by side effects. This is educational information, not medical advice.
Muscle symptoms are much less common with ezetimibe, which is a large part of why it is used in statin-intolerant patients. Myopathy and rhabdomyolysis have been reported rarely, mostly when combined with a statin, so new unexplained muscle pain or weakness should be reported to a clinician. This is educational information, not medical advice.
Ezetimibe can be taken with or without food at any time of day. Bile acid sequestrants such as cholestyramine reduce its absorption and should be separated by several hours. Plant sterol or stanol supplements work on the same absorption pathway, so their added effect is likely to be small. This is educational information, not medical advice.
Ezetimibe 10 mg once daily, either combined with a statin or (in EWTOPIA 75) with dietary counseling alone, across the cited cardiovascular outcome trials. Route reported: Oral tablet. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Ezetimibe — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Ezetimibe?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes(opens PubMed in a new tab)N Engl J Med · 2015 · PMID 26039521 · https://pubmed.ncbi.nlm.nih.gov/26039521/
- 2.PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis(opens PubMed in a new tab)BMJ · 2022 · PMID 35508321 · https://pubmed.ncbi.nlm.nih.gov/35508321/
- 3.Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy(opens PubMed in a new tab)Eur J Prev Cardiol · 2020 · PMID 31357887 · https://pubmed.ncbi.nlm.nih.gov/31357887/
- 4.Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions(opens PubMed in a new tab)Clin Pharmacokinet · 2005 · PMID 15871634 · https://pubmed.ncbi.nlm.nih.gov/15871634/
- 5.Ezetimibe(opens PubMed in a new tab)Am J Cardiovasc Drugs · 2003 · PMID 14727947 · https://pubmed.ncbi.nlm.nih.gov/14727947/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a603015.html
- PubChem CID 150311(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/150311
Verify at
Publisher search links for Ezetimibe. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Ezetimibe?
Plain-text summary, safe to quote verbatim:
Ezetimibe is a prescription cholesterol medicine that blocks the NPC1L1 transporter in the small intestine, cutting absorption of dietary and biliary cholesterol. It is typically taken in the morning. The reported plasma half-life is about 22 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/ezetimibe
Ezetimibe cheat sheet
DoseRoutine cheat sheet · Medication
Ezetimibe
Ezetimibe is a prescription cholesterol medicine that blocks the NPC1L1 transporter in the small intestine, cutting absorption of dietary and biliary cholesterol.
Evidence
Strong
3 human randomized trials and regulatory approval on file.
Studied range
Ezetimibe 10 mg once daily, either combined with a statin or (in EWTOPIA 75) with dietary counseling alone, across the cited cardiovascular outcome trials
Route
Oral tablet
Frequency studied
Once daily
Half-life
~22 h
Timing
in the morning
Prescription only (US)Ezetimibe (Zetia) is FDA-approved as a cholesterol absorption inhibitor, used alone or combined with a statin (e.g., Vytorin) for hyperlipidemia and cardiovascular risk reduction
Key references
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015)
- Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial (2022)
- Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial (2019)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/ezetimibe
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Ezetimibe — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ezetimibe
What compounds are similar to Ezetimibe?
Others in the medication category or studied for the same goals.